Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 255 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Photodynamic therapy Clear all
Completed Not applicable Interventional

A Small Clinical Study: Photodynamic Therapy to Treat Hidradenitis Suppurativa

NCT00395187
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Photodynamic Therapy
Procedure
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2007 · Synced Sep 2, 2026, 10:03 AM EDT
Terminated Phase 2 Interventional Results available

Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer

NCT02068157
View directory record Official record
Conditions
Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma
Interventions
Laboratory Biomarker Analysis, Photodynamic Therapy, Porfimer Sodium
Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 2, 2026, 10:03 AM EDT
Recruiting Phase 1 Interventional

Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer

NCT05918783
View directory record Official record
Conditions
Peripheral Lung Tumor
Interventions
Padeliporfin Vascular Targeted Photodynamic (VTP) therapy
Combination Product
Lead sponsor
Impact Biotech Ltd
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

NCT05060237
View directory record Official record
Conditions
Actinic Keratosis, Keratosis, Actinic, Keratosis
Interventions
BF-200 ALA and red light LED lamp
Combination Product
Lead sponsor
Biofrontera Bioscience GmbH
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Phoenix, Arizona • Greenwood Village, Colorado • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Not applicable Interventional Results available

Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains

NCT00556946
View directory record Official record
Conditions
Port Wine Stains
Interventions
Combined Photodynamic & Pulsed Dye Laser Treatment
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Sep 2, 2026, 10:03 AM EDT
Recruiting No phase listed Observational

Ablative Therapy in the Management of Prostate Cancer

NCT03492424
View directory record Official record
Conditions
Prostate Cancer
Interventions
cryotherapy
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2039
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

Photodynamic Therapy Plus Brachytherapy in Treating Patients With Lung Cancer

NCT00014066
View directory record Official record
Conditions
Lung Cancer
Interventions
hematoporphyrin derivative, brachytherapy
Drug · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 2, 2026, 10:03 AM EDT
Recruiting Phase 3 Interventional

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities

NCT07144852
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E.
Drug · Other · Device
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Phoenix, Arizona • Fremont, California • Castle Rock, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 2, 2026, 10:03 AM EDT
Recruiting Phase 1 Interventional

Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma

NCT05919238
View directory record Official record
Conditions
Locally Advanced Unresectable Pancreatic Adenocarcinoma
Interventions
Padeliporfin Vascular Targeted Photodynamic (VTP) therapy
Combination Product
Lead sponsor
Impact Biotech Ltd
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 10:03 AM EDT
Terminated Phase 2 Interventional Results available

Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas

NCT01966809
View directory record Official record
Conditions
Brain Tumor, Recurrent
Interventions
Photofrin photodynamic therapy.
Drug
Lead sponsor
Harry T Whelan, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 2, 2026, 10:03 AM EDT
Withdrawn Phase 3 Interventional

Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery

NCT00253617
View directory record Official record
Conditions
Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer
Interventions
porfimer sodium, adjuvant therapy, laser therapy, photodynamic therapy, phototherapy
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer

NCT00470496
View directory record Official record
Conditions
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Thyroid Cancer, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage I Adenoid Cystic Carcinoma of the Oral Cavity, Stage I Basal Cell Carcinoma of the Lip, Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage I Follicular Thyroid Cancer, Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage I Lymphoepithelioma of the Nasopharynx, Stage I Lymphoepithelioma of the Oropharynx, Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage I Mucoepidermoid Carcinoma of the Oral Cavity, Stage I Papillary Thyroid Cancer, Stage I Salivary Gland Cancer, Stage I Squamous Cell Carcinoma of the Hypopharynx, Stage I Squamous Cell Carcinoma of the Larynx, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage I Squamous Cell Carcinoma of the Oropharynx, Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage I Verrucous Carcinoma of the Larynx, Stage I Verrucous Carcinoma of the Oral Cavity, Stage II Adenoid Cystic Carcinoma of the Oral Cavity, Stage II Basal Cell Carcinoma of the Lip, Stage II Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage II Follicular Thyroid Cancer, Stage II Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage II Lymphoepithelioma of the Nasopharynx, Stage II Lymphoepithelioma of the Oropharynx, Stage II Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage II Mucoepidermoid Carcinoma of the Oral Cavity, Stage II Papillary Thyroid Cancer, Stage II Salivary Gland Cancer, Stage II Squamous Cell Carcinoma of the Hypopharynx, Stage II Squamous Cell Carcinoma of the Larynx, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Squamous Cell Carcinoma of the Oropharynx, Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage II Verrucous Carcinoma of the Larynx, Stage II Verrucous Carcinoma of the Oral Cavity
Interventions
HPPH, photodynamic therapy, conventional surgery
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2022 · Synced Sep 2, 2026, 10:03 AM EDT
Terminated Phase 2 Interventional

Topical PH-10 Aqueous Hydrogel and Photodynamic Therapy for Psoriasis

NCT00555646
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
PH-10 (rose bengal disodium 0.001%), Control
Drug
Lead sponsor
Provectus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

Novel Treatment for Port Wine Stain Birthmarks

NCT01924273
View directory record Official record
Conditions
Port-Wine Stain
Interventions
Talaporfin sodium
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 2, 2026, 10:03 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

NCT02082522
View directory record Official record
Conditions
Hilar Cholangiocarcinoma
Interventions
Photodynamic therapy-Photofrin, Stenting procedure, Chemotherapy regimen
Drug · Procedure
Lead sponsor
Concordia Laboratories Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 4 Interventional

Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment

NCT00680498
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Ranibizumab, Ranibizumab plus Photodynamic therapy
Drug
Lead sponsor
Illinois Retina Associates
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Oak Park, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Sep 2, 2026, 10:03 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Photodynamic Therapy-Induced Immune Modulation: Part III

NCT03643744
View directory record Official record
Conditions
Actinic Keratosis, Photodynamic Therapy
Interventions
Celecoxib 200mg, Placebo
Drug
Lead sponsor
Wright State University
Other
Eligibility
45 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Ranibizumab and Reduced Fluence PDT for AMD

NCT00527475
View directory record Official record
Conditions
Macular Degeneration
Interventions
ranibizumab, verteporfin
Drug
Lead sponsor
Texas Retina Associates
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Santa Barbara, California • Ann Arbor, Michigan • Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides

NCT00103246
View directory record Official record
Conditions
Lymphoma, Non-melanomatous Skin Cancer, Precancerous Condition
Interventions
silicon phthalocyanine 4
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 2, 2026, 10:03 AM EDT
Not listed Phase 2Phase 3 Interventional

Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma

NCT01755013
View directory record Official record
Conditions
Cholangiocarcinoma, Biliary Stricture, Biliary Obstruction, Bile Duct Cancer
Interventions
Photodynamic Therapy
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2017 · Synced Sep 2, 2026, 10:03 AM EDT
Terminated Phase 4 Interventional Results available

Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy

NCT01203878
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Photodynamic therapy, Imiquimod
Drug
Lead sponsor
Tennessee Clinical Research Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Englewood, Colorado • Charlotte, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 7, 2014 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris

NCT00673933
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Methyl aminolevulinate (MAL) PDT
Drug
Lead sponsor
Photocure
Industry
Eligibility
15 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Naperville, Illinois • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Results available

Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma

NCT01800838
View directory record Official record
Conditions
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome
Interventions
silicon phthalocyanine 4, photodynamic therapy, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
Kevin Cooper MD
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 2 Interventional

Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.

NCT00002167
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Tin ethyl etiopurpurin
Drug
Lead sponsor
Clinical Solutions
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 10:03 AM EDT